Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis

Table 2

Detailed results of network meta-analysis for pain (Bold) and function (Italic) (Data are standardised mean difference, from the top left to the bottom right, higher comparator vs. lower comparator, and their related 95% CI).

ALI	2.95 (-0.62 to 6.53)	2.46 (-1.53 to 6.45)	2.16 (-1.31 to 5.64)	0.14 (-4.32 to 4.60)	-0.99 (-4.25 to 2.27)
-3.11 (-6.85 to 0.62)	SCI	-0.49 (-3.22 to 2.24)	-0.79 (-2.18 to 0.59)	-2.82 (-6.01 to 0.37)	-3.94 (-5.40 to -2.48)
-3.65 (-7.82 to 0.53)	-0.53 (-3.39 to 2.33)	DLU	-0.30 (-2.91 to 2.30)	-2.33 (-6.14 to 1.49)	-3.45 (-5.76 to -1.15)
-1.77 (-5.40 to 1.85)	1.34 (-0.07 to 2.76)	1.87 (-0.84 to 4.59)	NSA	-2.02 (-5.23 to 1.18)	-3.15 (-4.36 to -1.94)
-0.54 (-5.20 to 4.13)	2.58 (-0.76 to 5.91)	3.11 (-0.89 to 7.10)	1.23 (-2.10 to 4.57)	OPI	-1.12 (-4.17 to 1.92)
1.11 (-2.29 to 4.52)	4.23 (2.70 to 5.76)	4.76 (2.35 to 7.17)	2.89 (1.65 to 4.13)	1.65 (-1.53 to 4.83)	PLA